- POAI
subsidiary Helomics helps oncologists individualize cancer treatment using
patient-derived tumor models to improve outcomes
- Helomics’
tumor genomic and drug response database is one of the largest in the
world with over 150,000 tumors across 137 cancer types
- Expected
CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine
industry
The relationship between a patient and their cancer is
personal: it’s specific, and it necessitates personalized treatment to be
defeated effectively. Unfortunately, oncologists’ ability to personalize
treatment for patients has largely been anything but, often resembling a
trial-and-error method. This is largely because we have few targeted treatments
or enough actionable data about how tumors with specific mutations respond to
drugs. One innovator in the cancer research space, Predictive Oncology Inc. (NASDAQ: POAI), is working to
change this dynamic by bringing its cutting-edge, AI-driven predictive models
of tumor drug response and outcome to cancer research. These models predict how
tumors respond to drugs and can be used for both clinical decision support,
i.e. individualizing a patient’s therapy as well as research into new
therapies, in partnership with the pharmaceutical and biotech industries.
With a mission to improve the standard of care for cancer
patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s
own living tumor to address challenges oncologists often face when assessing
patients and individualizing treatments. The clinically validated (in ovarian
cancer) cell-based functional platform is in use today and profiles patient
tumors, identifying key biomarkers and how the tumor responds to drugs and
helps the oncologist determine a tailored therapy for that patient.
Helomics’ is building AI-driven predictive models by
leveraging; a unique database of 150,000 tumor genomic and drug response
profiles gathered from over 15 years of clinical testing using its TruTumor
platform; access to over 15 years of outcome data from a national network of
oncologists; plus a physical biobank of tumor samples that is being sequenced
as part of its CancerQuest 2020 initiative (http://ibn.fm/B9mmE) to generate rich genomic profiles.
Along with subsidiaries TumorGenesis and Skyline Medical,
POAI brings precision medicine to the treatment of cancer through
collaborations with key players in the pharmaceutical, diagnostic and biotech
industries. According to Mordor Intelligence Inc, oncology is expected to have
the largest share of the precision medicine industry with estimated market
dominance in excess of 30% over other precision medicine segments, and a CAGR
of 10.3% from 2018 to 2024 (http://ibn.fm/8fqiH).
POAI is bringing precision medicine, or tailored medical
treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient derived (PDx) smart tumor profiling
platform to provide oncologists with a roadmap to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build AI-driven
models of tumor drug repose to improve outcomes for the patients of today and
tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
